top of page
NEWS and PRESS RELEASES
28 February 2024
CEBINA announces the launch of DanubeNeuro, an acceleration program transforming insightful neuroscience research into novel therapeutics
Read more
02 May 2023
CEBINA Announces Positive Results of a Phase 2 Clinical Study with COVID-19 patients and Azelastine Nasal Spray Published in a Peer-Reviewed Scientific Journal
Read more
10 December 2021
CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant
Read more
18 December 2023
Eveliqure initiates clinical safety and immunogenicity trials of its vaccine candidate against Shigellosis and ETEC in endemic populations in Bangladesh
Read more
23 February 2022
Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC
Read more
12 September 2023
Danube Labs: Call for Proposals - September 2023
Read more
04 July 2022
CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2
Read more
03 February 2022
Azelastine - the active drug in anti-allergy nasal sprays demonstrated to have potent anti-viral effect on the Omicron variant of
SARS-CoV-2
Read more
bottom of page